Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. ((2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-((6-((3s)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl)amino)-3-oxopropyl)phosphonic Acid
2. Act-246475
1. Selatogrel [inn]
2. 6dpk7o4pr7
3. Act-246475
4. 4-((r)-2-((6-((s)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl)amino)-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester
5. 1159500-34-1
6. 1-piperazinecarboxylic Acid, 4-((2r)-2-(((6-((3s)-3-methoxy-1-pyrrolidinyl)-2-phenyl-4-pyrimidinyl)carbonyl)amino)-1-oxo-3-phosphonopropyl)-, 1-butyl Ester
7. Unii-6dpk7o4pr7
8. Schembl2928412
9. Chembl4297589
10. Db15163
11. J3.559.357h
12. ((2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-((6-((3s)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl)amino)-3-oxopropyl)phosphonic Acid
13. [(2~{r})-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3~{s})-3-methoxypyrrolidin-1-yl]-2-phenyl-pyrimidin-4-yl]carbonylamino]-3-oxidanylidene-propyl]phosphonic Acid; [(2r)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3s)-3-methoxypyrrolidin-1-yl]-2-phenyl-pyrimidin-4-yl]carbonylamino]-3-oxidanylidene-propyl]phosphonic Acid; 4-((r)-2-((6-((s)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl)amino)-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester
14. 7y5
| Molecular Weight | 618.6 g/mol |
|---|---|
| Molecular Formula | C28H39N6O8P |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 12 |
| Exact Mass | 618.25669922 g/mol |
| Monoisotopic Mass | 618.25669922 g/mol |
| Topological Polar Surface Area | 175 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 986 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of acute myocardial infarction
Drugs in Development
Details:
Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2025
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Selatogrel PK/PD Comparison in Japanese vs Caucasian Healthy Participants
Details : Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2025
Details:
The collaboration focuses on the clinical development & commercialization of ACT-246475 (selatogrel), a reversible, highly selective P2Y12 inhibitor for treating Acute Myocardial Infarction.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Viatris
Deal Size: Undisclosed Upfront Cash: $350.0 million
Deal Type: Collaboration March 18, 2024
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Idorsia and Viatris Close Global Research Collaboration Transaction
Details : The collaboration focuses on the clinical development & commercialization of ACT-246475 (selatogrel), a reversible, highly selective P2Y12 inhibitor for treating Acute Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $350.0 million
March 18, 2024
Details:
The collaboration focuses on the clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, selective P2Y12 inhibitor for treating Acute Myocardial Infarction.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Viatris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 27, 2024
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Idorsia and Viatris Enter Into a Significant Global Research and Development Collaboration
Details : The collaboration focuses on the clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, selective P2Y12 inhibitor for treating Acute Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 27, 2024
Details:
Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myocardial Infarction.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 12, 2021
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Details : Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 12, 2021
Details:
Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2020
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects
Details : Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2020
Details:
Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2020
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
Details : Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2020
Details:
Saline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Sodium Chloride,Selatogrel,Rifampicin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2019
Lead Product(s) : Sodium Chloride,Selatogrel,Rifampicin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Saline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 23, 2019
Details:
ACT-246475 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2018
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects
Details : ACT-246475 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2018
Details:
Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myocardial Infarction.
Lead Product(s): Selatogrel,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 04, 2018
Lead Product(s) : Selatogrel,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
Details : Selatogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2018
Details:
ACT-246475 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Selatogrel,Clopidogrel,Prasugrel,Ticagrelor
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 13, 2018
Lead Product(s) : Selatogrel,Clopidogrel,Prasugrel,Ticagrelor
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-246475 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
45
PharmaCompass offers a list of Selatogrel API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Selatogrel manufacturer or Selatogrel supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Selatogrel manufacturer or Selatogrel supplier.
PharmaCompass also assists you with knowing the Selatogrel API Price utilized in the formulation of products. Selatogrel API Price is not always fixed or binding as the Selatogrel Price is obtained through a variety of data sources. The Selatogrel Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Selatogrel manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Selatogrel, including repackagers and relabelers. The FDA regulates Selatogrel manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Selatogrel API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Selatogrel supplier is an individual or a company that provides Selatogrel active pharmaceutical ingredient (API) or Selatogrel finished formulations upon request. The Selatogrel suppliers may include Selatogrel API manufacturers, exporters, distributors and traders.
Selatogrel Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Selatogrel GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Selatogrel GMP manufacturer or Selatogrel GMP API supplier for your needs.
A Selatogrel CoA (Certificate of Analysis) is a formal document that attests to Selatogrel's compliance with Selatogrel specifications and serves as a tool for batch-level quality control.
Selatogrel CoA mostly includes findings from lab analyses of a specific batch. For each Selatogrel CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Selatogrel may be tested according to a variety of international standards, such as European Pharmacopoeia (Selatogrel EP), Selatogrel JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Selatogrel USP).
